B
Brian Schwartz
Researcher at Bayer
Publications - 167
Citations - 18902
Brian Schwartz is an academic researcher from Bayer. The author has contributed to research in topics: Tivantinib & Sorafenib. The author has an hindex of 48, co-authored 150 publications receiving 17618 citations. Previous affiliations of Brian Schwartz include Bayer Corporation & University of Chicago.
Papers
More filters
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm,Christopher A. Carter,Mark Lynch,Timothy B. Lowinger,Jacques Dumas,Roger A. Smith,Brian Schwartz,Ronit Simantov,Susan Kelley +8 more
TL;DR: The discovery and continuing development of sorafenib is described, the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature.
Journal ArticleDOI
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Lawrence H. Schwartz,Sergio Ricci,Dino Amadori,Armando Santoro,Arie Figer,Jacques De Greve,Jean-Yves Douillard,Chetan Lathia,Brian Schwartz,Ian Taylor,M. Moscovici,Leonard B. Saltz +12 more
TL;DR: Although single-agent sorafenib has modest efficacy in HCC, the manageable toxicity and mechanisms of action support a role for combination regimens with other anticancer agents.
Journal ArticleDOI
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J. Ratain,Tim Eisen,Walter M. Stadler,Keith T. Flaherty,Stan B. Kaye,Gary L. Rosner,Martin Gore,Apurva A. Desai,Amita Patnaik,Henry Q. Xiong,Eric K. Rowinsky,James L. Abbruzzese,Chenghua Xia,Ronit Simantov,Brian Schwartz,Peter O'Dwyer +15 more
TL;DR: Sorafenib has significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with chronic daily therapy.
Journal ArticleDOI
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
Dirk Strumberg,Heike Richly,Ralf A. Hilger,Norbert Schleucher,Sonke Korfee,Mitra Tewes,Markus Faghih,E. Brendel,D. Voliotis,C. G. Haase,Brian Schwartz,Ahmad Awada,Rudolf Voigtmann,Max E. Scheulen,Siegfried Seeber +14 more
TL;DR: Based on the results of this study, BAY 43-9006 at 400 mg bid continuous is recommended for ongoing and future studies and was well tolerated and appeared to provide some clinical benefits.